Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.
Jan 22, 2014
0
0
Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic ...
Jul 27, 2012
0
0
A transformational new treatment for multiple sclerosis (MS) - the result of over three decades of research in Cambridge - was approved today by the EU agency responsible for regulating new drugs.
Sep 18, 2013
0
0
The genetic variability of a tumour could be a predictor for its aggressiveness: the greater the variability in gene expression, the more aggressive the tumour is likely to be. This is the hypothesis that the CNIO Structural ...
Feb 5, 2015
1
9
In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, ...
Dec 3, 2016
0
1
For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood.
Oct 4, 2018
0
1
September is Childhood Cancer Awareness Month. The most common type of childhood cancer is acute lymphocytic leukemia (ALL), a blood and bone marrow cancer that creates immature white blood cells that can't perform their ...
Sep 22, 2023
0
16
Chronic exposure to even small amounts of staph bacteria could be a risk factor for the chronic inflammatory disease lupus, Mayo Clinic research shows. Staph, short for Staphylococcus aureus, is a germ commonly found on the ...
Aug 8, 2012
0
1
A combination therapy pairing a small molecule inhibitor with monoclonal antibody immunotherapy improved patient outcomes for relapsed chronic lymphocytic leukemia (CLL), according to a Northwestern Medicine clinical trial ...
Aug 2, 2021
0
194
New research led by Derya Unutmaz, MD associate professor, the Departments of Pathology, Medicine, and Microbiology at NYU School of Medicine and Mark Sundrud, PhD, of Tempero Pharmaceuticals, Inc., has identified a novel ...
Aug 10, 2011
0
0
